<DOC>
	<DOCNO>NCT02716974</DOCNO>
	<brief_summary>To assess safety treat men oligometastatic prostate cancer follow therapy : ( 1st ) Systemic chemo-hormonal therapy 6-months ( ~24 week ) neoadjuvant androgen deprivation 6 cycle chemotherapy , ( 2nd ) definitive local tumor control prostatectomy +/- adjuvant radiation therapy , ( 3rd ) consolidative stereotactic radiation oligometastatic lesion . The men receive total 1 year androgen deprivation . Androgen blockade throughout course treatment .</brief_summary>
	<brief_title>A Study Definitive Therapy Treat Prostate Cancer</brief_title>
	<detailed_description>Neoadjuvant treatment ( month 1 ~6 ) : All patient treat 6 month androgen deprivation , plus 6 cycle docetaxel chemotherapy . Following docetaxel therapy , patient PSA response least 50 % decrease baseline , proceed maximum consolidative therapy . Local consolidation ( month 7 though ~11 ) : After completion neoadjuvant therapy , men treat definitive local therapy radical prostatectomy ( RP ) +/- adjuvant radiation therapy ( RT ) . After definitive local therapy , patient treat consolidative stereotactic body radiation therapy ( SBRT ) metastatic site . Systemic consolidation : Patients continue androgen deprivation total 1 year . They follow clinically monitor serum testosterone PSA 2-years completion systemic consolidation . Androgen blockade throughout course treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Willing able provide write informed consent . 2 . Age ≥ 18 year 3 . Eastern cooperative group ( ECOG ) performance status ≤2 4 . Documented histologically confirm adenocarcinoma prostate 5 . Willing undergo follow therapy : ( 1st ) Systemic chemohormonal therapy 6months ( ~24 week ) neoadjuvant androgen deprivation 6 cycle chemotherapy , ( 2nd ) definitive local tumor control prostatectomy +/ adjuvant radiation therapy , ( 3rd ) consolidative stereotactic radiation oligometastatic lesion . Additionally , must willing treat full year androgen deprivation . 6 . Oligometastatic prostate cancer : Stage T14 , N01 M1ab ( 5 metastatic lesion include bone lesion nonregional lymph node see bone scan , contrast enhance CT scan , PET scan ) 7 . Able swallow study drug whole tablet 1 . Prior local therapy treat prostate cancer ( e.g . radical prostatectomy , radiation therapy , brachytherapy ) 2 . Prior therapy metastatic site . 3 . Prior ongoing systemic therapy prostate cancer include , limited : 1 . Hormonal therapy ( e.g . leuprolide , goserelin , triptorelin , degarelix ) 2 . CYP17 inhibitor ( e.g . ketoconazole ) 3 . Antiandrogens ( e.g . bicalutamide , nilutamide ) 4 . Second generation antiandrogens ( e.g . enzalutamide , abiraterone ) 5 . Immunotherapy ( e.g . sipuleucelT , ipilimumab ) 6 . Chemotherapy ( e.g . docetaxel , cabazitaxel ) *Note : may enrol hormone therapy recently initiate ( &lt; 90 day duration ) ) . In event hormone therapy initiate prior study enrollment , clock 1 year androgen deprivation would begin time therapy initiation , rather study enrollment . 4 . Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study . 5 . Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule . 6 . Abnormal bone marrow function [ absolute neutrophil count ( ANC ) &lt; 1500/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin &lt; 9 g/dL ] 7 . Abnormal liver function ( bilirubin &gt; ULN ; AST , ALT &gt; 2.5 x upper limit normal ) 8 . Creatinine clearance ≥ 30 mL/min . CrCl calculate sue CockcroftGault formula . 9 . PT , INR ≤ 1.5 x ULN ( except therapeutic anticoagulation case patient enrol stable anticoagulation level appropriate condition good clinical practice ) . 10 . Active cardiac disease define active angina , symptomatic congestive heart failure , myocardial infarction within previous six month . 11 . Prior history malignancy past 3 year exception basal cell squamous cell carcinoma skin . Other malignancy consider low potential progress may enrol discretion PI .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lupron</keyword>
	<keyword>Bicalutamide</keyword>
	<keyword>Docetaxel</keyword>
</DOC>